Notice of first launch, interruption or termination of supply of a human drug
 Date ▲HolderCodeDrugDate fromSubject
 15.5.2023Fresenius Kabi s.r.o. (FRK-CZ-3)8423DDexmedetomidine Kabi 100 mikrogramov/ml (con inf 10x2 ml (liek.inj.skl.))15.5.2023R
 15.5.2023Fresenius Kabi s.r.o. (FRK-CZ-3)4150BGemcitabine Kabi 38 mg/ml infúzny koncentrát (con inf 1x26,3 ml/1000 mg (liek.inj.skl.))15.5.2023R
 15.5.2023Fresenius Kabi s.r.o. (FRK-CZ-3)4202ASmofKabiven (emu inf 6x493 ml (vak Biofin))15.5.2023R
 15.5.2023Angelini Pharma Česká republika s.r.o. (AIP-2)28993ERDOMED 3,5 % (plu por 1x50 g (fľ.skl.jantárová))11.5.2023O
 15.5.2023Fresenius Kabi s.r.o. (FRK-CZ-3)1606CPalonosetron Fresenius Kabi 250 mikrogramov injekčný roztok (sol inj 1x5 ml/250 µg (liek.inj.skl.))15.5.2023O
 15.5.2023CSL Behring GmbH (CSL)88206Alburex 20 (sol inf 1x100 ml/20 g (liek.skl.inj.))15.5.2023R
 15.5.2023CSL Behring GmbH (CSL)50934Privigen 100 mg/ml infúzny intravenózny roztok (sol inf 1x50 ml (liek.inj.skl.))15.5.2023R
 15.5.2023CSL Behring GmbH (CSL)50935Privigen 100 mg/ml infúzny intravenózny roztok (sol inf 1x100 ml (liek.inj.skl.))15.5.2023R
 15.5.2023CSL Behring GmbH (CSL)50936Privigen 100 mg/ml infúzny intravenózny roztok (sol inf 1x200 ml (liek.inj.skl.))15.5.2023R
 15.5.2023CSL Behring GmbH (CSL)80027Privigen 100 mg/ml infúzny intravenózny roztok (sol inf 1x25 ml (liek.inj.skl.))15.5.2023R
 15.5.2023Glenmark Pharmaceuticals s.r.o. (GLM-CZ)7643DGabapentin Glenmark 300 mg tvrdé kapsuly (cps dur 200x300 mg (blis.PVC/PVDC/Al))15.5.2023O
 15.5.2023B.Braun Melsungen AG (BME)21435Remifentanil B. Braun 2 mg (plc ifu 5x2 mg (liek.inj.skl.))15.5.2023R
 15.5.2023Johnson & Johnson, s.r.o. (JHN-SK-1)49919Concerta 18 mg tablety s predĺženým uvoľňovaním (tbl plg 30x18 mg (fľ.HDPE))12.5.2023Z
 15.5.2023AstraZeneca AB (AZC)2563DFasenra 30 mg injekčný roztok naplnený v pere (sol ira 1x1 ml/30 mg (striek.inj.napl.skl. v pere))9.5.2023U
 15.5.2023AstraZeneca AB (AZC)7363CFasenra 30 mg injekčný roztok naplnený v injekčnej striekačke (sol iru 1x1 ml/30 mg (striek.inj.napl.skl.))9.5.2023U

Subject means:
U-Placement of medicine to Slovakian market, R-Discontinuation of medicine supply to Slovakian market,
O-Resumption of medicine supply to Slovakian market, Z-Cancelation of medicine supply to Slovakian market


Date from
From
To



 
Processed by the system MCR.Prerusenie (8.0)